The trajectory of Viagra presents a challenging picture for those considering investment. While the initial introduction generated substantial gains, the lapse of its exclusive rights opened the avenue to cheaper versions, dramatically reducing revenue. This poses a particular risk for firms depending on comparable blockbuster offerings, suggesting

The story of Viagra, and its parent company copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in sales , its intellectual property lapse created a flood of generic competition , significantly diminishing its market share . While certain pharmaceutical companies may attempt to capitalize on rel